Gilead Pushes Cancer Pipeline; Enters Phase III with PI3K DrugBioWorld OnlineIn the trial, called Study 116, 160 patients at about 70 sites in the US and Europe will be randomized to receive eight infusions of Rituxan (rituximab, Biogen Idec Inc. and R…
Novel Biologic Targets LupusMedPage TodayEpratuzumab differs from rituximab in that it depletes only about 30% of B cells, she explained at the annual meeting of the British Society for Rheumatology. This partial depletion causes phosphorylation and in…
Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment …SunHerald.comGS-1101 is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform and is being evaluated in combination wi…
In Mexico, New Guidelines Are Now in Effect for the Market Authorization of …MarketWatch (press release)For example, Probiomed already sells six non-originator biologics, including Kikuzubam (rituximab), which is Probiomed's version of Roche'…
Pharmazeutische Zeitung onlineNebenwirkung DiabetesPharmazeutische Zeitung onlineDazu gehören der mTOR-Inhibitor Sirolimus und der monoklonale Antikörper Basiliximab, der sich gegen Interleukin-2 richtet. Behandelt wird ein Posttransplantationsdiabet…
Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment …EON: Enhanced Online News (press release)GS-1101 is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform and is being…
Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment …MarketWatch (press release)GS-1101 is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform and is being evaluated in …
Mass High TechBiogen Idec Q1 revenues up 7 percentMass High Tech… has announced that its first-quarter revenues for the three months ending on March 31 were $1.3 billion, up 7 percent from the same time a year before, due largely to increased sales o…
Mass High TechBiogen Idec's CEO Discusses Q1 2012 Results – Earnings Call TranscriptSeeking AlphaAt the American Academy of Neurology meeting lastly, our pipeline was the subject of 49 platform presentations and posters, including new data for TYSA…
UK patients to be barred from first new lupus drug in 50 yearsPharma TimesIn addition, some patients with severe disease currently receive rituximab off-label. Although it is not licensed for this use, the Committee would have liked to see data compari…